May 17, 2016 / 6:10 AM / a month ago

BRIEF-Novartis Announces EU Approval Of MS Drug Mayzent For Certain Adult Patients

Jan 20 (Reuters) - Novartis AG:

* NOVARTIS ANNOUNCES EU APPROVAL OF MAYZENT® (SIPONIMOD) FOR ADULT PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) WITH ACTIVE DISEASE

* APPROVAL IS BASED ON PHASE III EXPAND TRIAL Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below